prospect
studi
describ
respons
major
vaccin
among
larg
cohort
adult
autolog
allogen
hsct
recipi
reallif
set
impact
preand
posttranspl
factor
ie
graftversushostdiseas
vaccin
respons
analys
innov
immun
function
assay
assess
innat
adapt
immun
respons
hsct
recipi
transcriptom
protein
cellular
level
immedi
month
primari
vaccin
vaccin
respons
correl
function
immun
statu
immun
initi
upon
haematologist
referr
might
creat
bia
inclus
impact
vaccin
respons
biomark
immun
function
could
help
optim
vaccin
schedul
individu
level
address
valid
specif
studi
result
obtain
regard
immun
respons
vaccin
compar
futur
similar
data
obtain
hcst
protocol
control
healthi
volunt
enrol
test
immun
function
assay
healthi
volunt
recruit
among
donor
blood
bank
etabliss
du
sang
ef
lyon
accord
ef
standard
procedur
blood
donat
inform
consent
obtain
healthi
donor
person
data
anonymis
time
blood
donat
prior
transfer
blood
research
laboratori
particip
workflow
vaccheminf
cohort
describ
figur
recipi
age
year
includ
first
visit
explan
given
implement
vaccin
schedul
preblood
test
assess
ii
postvaccin
assess
visit
monitor
vaccin
respons
toler
fight
immun
function
assay
endpoint
address
object
mention
primari
endpoint
measur
vaccinespecif
antibodi
titr
express
vaccin
respons
percentag
respond
geometr
mean
titr
gmt
immedi
group
blood
marrow
transplant
ebmt
classif
infect
infecti
agentrel
reactiv
diseas
updat
latest
guidelin
list
full
definit
criteria
provid
tabl
peripher
blood
tand
blymphocyt
subset
natur
killer
nk
count
box
event
variabl
correspond
appli
french
vaccin
schedul
second
immun
function
assay
consist
induc
lymphocyt
prolifer
measur
releas
supernat
respons
ex
vivo
stimul
standard
mitogen
phytohemagglutinin
pha
peripher
blood
mononuclear
cell
pbmc
isol
fresh
heparin
blood
sampl
ficol
densiti
gradient
centrifug
eurobio
le
uli
franc
incub
cultur
medium
overnight
pbmc
stimul
duplic
pha
remel
oxoid
thermo
fisher
scientif
usa
cell
cultur
plate
hour
upon
incub
supernat
harvest
quantif
use
platform
cell
harvest
cell
prolifer
determin
incorpor
edu
hour
cell
use
edu
flow
kit
life
technolog
carlsbad
california
usa
first
cell
stain
allophycocyanin
apc
label
monoclon
antibodi
beckman
coulter
brea
california
usa
fix
fix
solut
beckman
f
r
p
e
e
r
r
e
v
e
w
n
l
coulter
brea
california
usa
edu
activ
reaction
cocktail
contain
alexa
azid
compon
clickit
flow
cytometri
analys
perform
navio
flow
cytomet
beckman
coulter
brea
california
usa
cell
first
select
among
total
event
base
monoparametr
apc
histogram
percentag
edu
cell
among
cell
along
geometr
mean
fluoresc
intens
mfi
popul
measur
among
cell
record
use
immun
function
assay
describ
innov
approach
consist
appropri
associ
confid
interv
ci
gmt
mean
ci
comput
transform
titr
transform
back
origin
unit
exponenti
vaccin
target
low
moder
respond
rate
associ
respondersnonrespond
endpoint
factor
establish
use
logist
regress
factor
associ
endpoint
signific
level
p
kept
multivari
logist
regress
model
model
adjust
two
three
confound
factor
chosen
accord
evidencebas
literatur
case
relaps
haematolog
diseas
case
death
followup
case
loss
followup
patient
includ
analysi
provid
least
preand
one
postvaccin
assess
avail
analys
base
side
pvalu
statist
signific
defin
p
conduct
r
version
final
appropri
multipl
imput
ie
random
taken
consider
case
relev
amount
miss
valu
inform
consent
identif
recipi
includ
studi
kept
anonym
protect
cryptograph
code
data
anonym
extract
medic
record
hcl
softwar
inform
sign
consent
regist
computer
record
recipi
full
inform
object
workflow
studi
given
possibl
provid
recipi
refus
particip
exit
studi
whenev
chosen
comprehens
notic
distribut
recipi
summaris
protocol
followup
studi
dissemin
result
commun
scientif
meet
submit
public
peerreview
journal
prospect
cohort
includ
consecut
adult
hsct
recipi
complet
vaccin
schedul
full
preand
postvaccin
assess
independ
complic
immunomodulatori
therapi
test
schedul
reallif
set
anoth
interest
longterm
assess
antibodi
hsct
better
immun
recoveri
secondli
recipi
receiv
intraven
ig
transplant
may
overestim
assess
serolog
respons
vaccin
also
acknowledg
bia
due
serolog
method
notabl
pneumococcu
may
optim
altern
method
measur
specif
antibodi
vitro
opsonis
test
function
assay
measur
deeper
aspect
immun
respons
vaccin
precis
variabl
collect
databas
potenti
impact
immun
function
consequ
alter
readout
interpret
specif
sensit
assay
milieu
interieur
consortium
set
preliminari
refer
rang
healthi
immun
respons
natur
varianc
similarli
order
map
immun
disord
healthi
donor
vaccheminf
studi
provid
refer
panel
essenti
evalu
inrang
outrang
scale
addit
durat
followup
current
project
last
month
popul
patient
close
monitor
refer
physician
virtual
loss
followup
ad
valu
might
extend
durat
followup
upon
recipi
agreement
sustain
qualiti
inform
nonetheless
acknowledg
potenti
confound
import
number
collect
variabl
sampl
size
may
allow
complex
analysi
may
like
statist
underpow
prospect
studi
describ
respons
major
vaccin
among
cohort
adult
autolog
allogen
hsct
recipi
reallif
set
secondari
outcom
studi
offer
opportun
assess
impact
preand
tetanu
diphtheria
administr
hsct
use
antibodi
titr
refer
method
f
r
p
e
e
r
r
e
v
e
w
n
l
control
healthi
volunt
enrol
test
immun
function
assay
healthi
volunt
recruit
among
donor
blood
bank
etabliss
du
sang
ef
lyon
accord
ef
standard
procedur
blood
donat
inform
consent
obtain
healthi
donor
person
data
anonymis
time
blood
donat
prior
transfer
blood
research
laboratori
particip
workflow
vaccheminf
cohort
describ
figur
inform
consent
identif
recipi
includ
studi
kept
anonym
protect
cryptograph
code
data
anonym
extract
medic
record
hcl
softwar
inform
sign
consent
regist
computer
record
recipi
full
inform
object
workflow
studi
given
possibl
provid
recipi
refus
particip
exit
studi
whenev
chosen
comprehens
notic
distribut
recipi
summaris
protocol
followup
studi
later
hsct
better
immun
recoveri
secondli
recipi
receiv
intraven
ig
transplant
may
overestim
assess
serolog
respons
vaccin
also
acknowledg
bia
due
serolog
method
notabl
